{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T22:01:41Z","timestamp":1783116101870,"version":"3.54.6"},"reference-count":75,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["bmn.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Immunology"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.coi.2025.102637","type":"journal-article","created":{"date-parts":[[2025,8,9]],"date-time":"2025-08-09T02:52:30Z","timestamp":1754707950000},"page":"102637","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Can sarcoidosis be cured?"],"prefix":"10.1016","volume":"96","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1096-0596","authenticated-orcid":false,"given":"Paolo","family":"Spagnolo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc A","family":"Judson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.coi.2025.102637_bib1","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1001\/jama.2022.1570","article-title":"Diagnosis and treatment of pulmonary sarcoidosis: a review","volume":"327","author":"Belperio","year":"2022","journal-title":"JAMA"},{"key":"10.1016\/j.coi.2025.102637_sbref2","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2024.103247","article-title":"The immunopathogenesis of sarcoidosis","volume":"149","author":"Miedema","year":"2024","journal-title":"J Autoimmun"},{"key":"10.1016\/j.coi.2025.102637_bib3","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.537382","article-title":"Sarcoidosis epidemiology: race matters","volume":"11","author":"Hena","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.coi.2025.102637_sbref4","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1164\/rccm.202106-1366CI","article-title":"Management of advanced pulmonary sarcoidosis","volume":"205","author":"Gupta","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.coi.2025.102637_bib5","first-page":"525","article-title":"Prognostic factors predicting the outcome of sarcoidosis: an analysis of 818 patients","volume":"52","author":"Neville","year":"1983","journal-title":"Q J Med"},{"key":"10.1016\/j.coi.2025.102637_bib6","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1097\/00063198-199909000-00005","article-title":"Clinical courses and prognoses of pulmonary sarcoidosis","volume":"5","author":"Nagai","year":"1999","journal-title":"Curr Opin Pulm Med"},{"key":"10.1016\/j.coi.2025.102637_bib7","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1378\/chest.111.3.623","article-title":"Outcome in sarcoidosis. The relationship of relapse to corticosteroid therapy","volume":"111","author":"Gottlieb","year":"1997","journal-title":"Chest"},{"key":"10.1016\/j.coi.2025.102637_bib8","first-page":"56","article-title":"Defining the clinical outcome status (COS) in sarcoidosis: results of WASOG Task Force","volume":"28","author":"Baughman","year":"2011","journal-title":"Sarcoidosis Vasc Diffuse\u00a0Lung Dis"},{"key":"10.1016\/j.coi.2025.102637_bib9","first-page":"167","article-title":"Sarcoidosis: a long-term follow up study","volume":"17","author":"Chappell","year":"2000","journal-title":"Sarcoidosis Vasc Diffuse\u00a0Lung Dis"},{"key":"10.1016\/j.coi.2025.102637_bib10","first-page":"158","article-title":"The prognosis of pulmonary sarcoidosis in Finland and Hokkaido, Japan. A comparative five-year study of biopsy-proven cases","volume":"17","author":"Pietinalho","year":"2000","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"10.1016\/j.coi.2025.102637_bib11","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1159\/000196341","article-title":"Clinical factors predicting persistence of activity in sarcoidosis: a multivariate analysis of 193 cases","volume":"61","author":"Mana","year":"1994","journal-title":"Respiration"},{"key":"10.1016\/j.coi.2025.102637_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2022.107063","article-title":"Why doesn't anyone want to cure sarcoidosis?: the neglect of disease termination","volume":"213","author":"Judson","year":"2023","journal-title":"Respir Med"},{"key":"10.1016\/j.coi.2025.102637_bib13","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/j.chest.2018.03.056","article-title":"Drug-induced sarcoidosis-like reactions","volume":"154","author":"Chopra","year":"2018","journal-title":"Chest"},{"key":"10.1016\/j.coi.2025.102637_bib14","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1111\/joim.12991","article-title":"Drug-induced sarcoidosis: an overview of the WHO pharmacovigilance database","volume":"288","author":"Aubart","year":"2020","journal-title":"J Intern Med"},{"key":"10.1016\/j.coi.2025.102637_bib15","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.reuma.2018.10.004","article-title":"Pulmonary sarcoidosis: prognostic factors at diagnosis in patients from North of Portugal","volume":"16","author":"Silva","year":"2020","journal-title":"Reumatol Clin"},{"key":"10.1016\/j.coi.2025.102637_bib16","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1007\/s10067-019-04507-3","article-title":"Risk factors of relapse in pulmonary sarcoidosis treated with corticosteroids","volume":"38","author":"Zheng","year":"2019","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.coi.2025.102637_bib17","first-page":"34","article-title":"Factor analysis of sarcoidosis phenotypes at two referral centers in Brazil","volume":"28","author":"Rodrigues","year":"2011","journal-title":"Sarcoidosis Vasc Diffuse\u00a0Lung Dis"},{"key":"10.1016\/j.coi.2025.102637_bib18","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1093\/qjmed\/hcl038","article-title":"Presenting characteristics as predictors of duration of treatment in sarcoidosis","volume":"99","author":"Baughman","year":"2006","journal-title":"QJM"},{"key":"10.1016\/j.coi.2025.102637_bib19","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1097\/00005792-199903000-00001","article-title":"The clinical management of sarcoidosis. A 50-year experience at the Johns Hopkins Hospital","volume":"78","author":"Johns","year":"1999","journal-title":"Medicine"},{"key":"10.1016\/j.coi.2025.102637_bib20","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1164\/ajrccm.149.4.8143052","article-title":"Outcome of the treatment for sarcoidosis","volume":"149","author":"Hunninghake","year":"1994","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.coi.2025.102637_bib21","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1016\/j.rmed.2013.10.014","article-title":"Frequency of acute worsening events in fibrotic pulmonary sarcoidosis patients","volume":"107","author":"Baughman","year":"2013","journal-title":"Respir Med"},{"key":"10.1016\/j.coi.2025.102637_bib22","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.rmed.2012.11.011","article-title":"Severity of pulmonary involvement and (18)F-FDG PET activity in sarcoidosis","volume":"107","author":"Mostard","year":"2013","journal-title":"Respir Med"},{"key":"10.1016\/j.coi.2025.102637_bib23","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.rmed.2019.03.012","article-title":"Quantifying the relationship between symptoms at presentation and the prognosis of sarcoidosis","volume":"152","author":"Judson","year":"2019","journal-title":"Respir Med"},{"key":"10.1016\/j.coi.2025.102637_bib24","first-page":"29","article-title":"Sarcoidosis: epidemiology and prognosis. A 15-year European study","volume":"130","author":"Hillerdal","year":"1984","journal-title":"Am Rev Respir Med"},{"key":"10.1016\/j.coi.2025.102637_bib25","first-page":"158","article-title":"T-cell receptor genes in sarcoidosis","volume":"15","author":"Moller","year":"1998","journal-title":"Sarcoidosis Vasc Diffuse\u00a0Lung Dis"},{"key":"10.1016\/j.coi.2025.102637_bib26","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.01340","article-title":"Environmental risk factors for sarcoidosis","volume":"11","author":"Judson","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.coi.2025.102637_bib27","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2025.1558049","article-title":"A review of sarcoidosis etiology, diagnosis and treatment","volume":"12","author":"Waly","year":"2025","journal-title":"Front Med"},{"key":"10.1016\/j.coi.2025.102637_bib28","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/S0140-6736(04)15523-2","article-title":"Beryllium exposure and chronic beryllium disease","volume":"363","author":"Infante","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.coi.2025.102637_sbref29","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1056\/NEJMra2101555","article-title":"Challenges of sarcoidosis and its management","volume":"385","author":"Drent","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coi.2025.102637_bib30","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1164\/rccm.201006-0865CI","article-title":"A concise review of pulmonary sarcoidosis","volume":"183","author":"Baughman","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.coi.2025.102637_bib31","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1111\/j.1440-1843.2009.01518.x","article-title":"Clinical outcomes in sarcoidosis after cessation of infliximab treatment","volume":"14","author":"Panselinas","year":"2009","journal-title":"Respirology"},{"key":"10.1016\/j.coi.2025.102637_bib32","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1093\/rheumatology\/ker316","article-title":"Increased IL-17A expression in granulomas and in circulating memory T cells in sarcoidosis","volume":"51","author":"Ten Berge","year":"2012","journal-title":"Rheumatology"},{"key":"10.1016\/j.coi.2025.102637_bib33","doi-asserted-by":"crossref","first-page":"4414","DOI":"10.4049\/jimmunol.0903332","article-title":"Essential role of IL-17A in the formation of a mycobacterial infection-induced granuloma in the lung","volume":"184","author":"Okamoto Yoshida","year":"2010","journal-title":"J Immunol"},{"key":"10.1016\/j.coi.2025.102637_bib34","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1164\/rccm.201503-0418OC","article-title":"Identification of immune-relevant factors conferring sarcoidosis genetic risk","volume":"192","author":"Fischer","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.coi.2025.102637_bib35","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1136\/thx.2010.140319","article-title":"Sarcoidosis is a Th1\/Th17 multisystem disorder","volume":"66","author":"Facco","year":"2011","journal-title":"Thorax"},{"key":"10.1016\/j.coi.2025.102637_bib36","doi-asserted-by":"crossref","first-page":"15036","DOI":"10.1074\/jbc.272.23.15036","article-title":"The T cell-directed CC chemokine TARC is a highly specific biological ligand for CC chemokine receptor 4","volume":"272","author":"Imai","year":"1997","journal-title":"J Biol Chem"},{"key":"10.1016\/j.coi.2025.102637_bib37","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.alit.2018.02.011","article-title":"TARC expression in the circulation and cutaneous granulomas correlates with disease severity and indicates Th2-mediated progression in patients with sarcoidosis","volume":"67","author":"Nguyen","year":"2018","journal-title":"Allergol Int"},{"key":"10.1016\/j.coi.2025.102637_bib38","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1146\/annurev-immunol-101921-041206","article-title":"IL-4 and IL-13: regulators and effectors of wound repair","volume":"41","author":"Allen","year":"2023","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.coi.2025.102637_bib39","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2018.01516","article-title":"In situ humoral immunity to vimentin in HLA-DRB1*03(+) patients with pulmonary\u00a0sarcoidosis","volume":"9","author":"Kinloch","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.coi.2025.102637_bib40","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1183\/13993003.01791-2015","article-title":"Specific antigen(s) in sarcoidosis: a link to autoimmunity?","volume":"47","author":"Zissel","year":"2016","journal-title":"Eur Respir J"},{"key":"10.1016\/j.coi.2025.102637_bib41","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1097\/MCP.0000000000000809","article-title":"Sarcoidosis and autoimmunity","volume":"27","author":"Song","year":"2021","journal-title":"Curr Opin Pulm Med"},{"key":"10.1016\/j.coi.2025.102637_bib42","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s10238-021-00737-5","article-title":"Associations between sarcoidosis, autoimmune diseases, and autoantibodies: a single-center retrospective study in China","volume":"22","author":"Shi","year":"2022","journal-title":"Clin Exp Med"},{"key":"10.1016\/j.coi.2025.102637_bib43","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0170285","article-title":"Proteomic analysis of Kveim reagent identifies targets of cellular immunity in sarcoidosis","volume":"12","author":"Eberhardt","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.coi.2025.102637_bib44","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1183\/09031936.00224513","article-title":"Rituximab in the treatment of refractory pulmonary sarcoidosis","volume":"43","author":"Sweiss","year":"2014","journal-title":"Eur Respir J"},{"key":"10.1016\/j.coi.2025.102637_bib45","article-title":"Corticosteroids for pulmonary sarcoidosis","volume":"2005","author":"Paramothayan","year":"2005","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.coi.2025.102637_bib46","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1111\/j.1749-6632.1986.tb18548.x","article-title":"The possible influence of corticosteroid therapy on the natural course of pulmonary sarcoidosis. Late results of a continuing clinical study","volume":"465","author":"Eule","year":"1986","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.coi.2025.102637_bib47","first-page":"142","article-title":"Sarcoidosis in Kyoto (1963-1986)","volume":"5","author":"Izumi","year":"1988","journal-title":"Sarcoidosis"},{"key":"10.1016\/j.coi.2025.102637_bib48","first-page":"280","article-title":"The indications for the treatment of sarcoidosis: Well\u2019s Law","volume":"34","author":"Baughman","year":"2017","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"10.1016\/j.coi.2025.102637_bib49","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1136\/thx.51.3.238","article-title":"British Thoracic Society Sarcoidosis study: effects of long term corticosteroid treatment","volume":"51","author":"Gibson","year":"1996","journal-title":"Thorax"},{"key":"10.1016\/j.coi.2025.102637_bib50","first-page":"119","article-title":"The clinical course of sarcoidosis: presentation, diagnosis, and treatment in a large white and black cohort in the United States","volume":"29","author":"Judson","year":"2012","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"10.1016\/j.coi.2025.102637_bib51","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1183\/09031936.00187410","article-title":"Stage IV sarcoidosis: comparison of survival with the general population and causes of death","volume":"38","author":"Nardi","year":"2011","journal-title":"Eur Respir J"},{"key":"10.1016\/j.coi.2025.102637_sbref52","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.04079-2020","article-title":"ERS clinical practice guidelines on treatment of sarcoidosis","volume":"58","author":"Baughman","year":"2021","journal-title":"Eur Respir J"},{"key":"10.1016\/j.coi.2025.102637_bib53","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1016\/j.amjcard.2015.12.033","article-title":"Effect of discontinuation of prednisolone therapy on risk of cardiac mortality associated with worsening left ventricular dysfunction in cardiac sarcoidosis","volume":"117","author":"Nagai","year":"2016","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.coi.2025.102637_sbref54","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.chest.2017.07.008","article-title":"Predictors of mortality in pulmonary sarcoidosis","volume":"153","author":"Kirkil","year":"2018","journal-title":"Chest"},{"key":"10.1016\/j.coi.2025.102637_bib55","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1378\/chest.15-0615","article-title":"Histopathology of explanted lungs from patients with a diagnosis of pulmonary sarcoidosis","volume":"149","author":"Zhang","year":"2016","journal-title":"Chest"},{"key":"10.1016\/j.coi.2025.102637_bib56","first-page":"372","article-title":"Role of serial F-18 FDG PET\/CT scans in assessing treatment response and predicting relapses in patients with symptomatic sarcoidosis","volume":"2016","author":"Maturu","year":"2016","journal-title":"Sarcoidosis Vasc Diffuse\u00a0Lung Dis"},{"key":"10.1016\/j.coi.2025.102637_bib57","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1183\/09031936.00227014","article-title":"Effectiveness of infliximab in refractory FDG PET-positive sarcoidosis","volume":"46","author":"Vorselaars","year":"2015","journal-title":"Eur Respir J"},{"key":"10.1016\/j.coi.2025.102637_sbref58","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1056\/NEJMoa2501443","article-title":"First-line treatment of pulmonary sarcoidosis with prednisone or methotrexate","volume":"393","author":"Kahlmann","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coi.2025.102637_bib59","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.545413","article-title":"Treatment of sarcoidosis: a multidisciplinary approach","volume":"11","author":"Gerke","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.coi.2025.102637_bib60","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2020.106081","article-title":"Corticosteroid refractory sarcoidosis","volume":"171","author":"Goldman","year":"2020","journal-title":"Respir Med"},{"key":"10.1016\/j.coi.2025.102637_bib61","first-page":"185","article-title":"Exaggerated TNFalpha release of alveolar macrophages in corticosteroid resistant sarcoidosis","volume":"19","author":"Ziegenhagen","year":"2002","journal-title":"Sarcoidosis Vasc Diffuse\u00a0Lung Dis"},{"key":"10.1016\/j.coi.2025.102637_bib62","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.rmed.2017.09.003","article-title":"Toxicity risk from glucocorticoids in sarcoidosis patients","volume":"132","author":"Khan","year":"2017","journal-title":"Respir Med"},{"key":"10.1016\/j.coi.2025.102637_bib63","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/j.rmed.2015.01.019","article-title":"The effect of corticosteroids on quality of life in a sarcoidosis clinic: the results of a propensity analysis","volume":"109","author":"Judson","year":"2015","journal-title":"Respir Med"},{"key":"10.1016\/j.coi.2025.102637_bib64","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.rmed.2016.02.011","article-title":"The three tiers of screening for sarcoidosis organ involvement","volume":"113","author":"Judson","year":"2016","journal-title":"Respir Med"},{"key":"10.1016\/j.coi.2025.102637_bib65","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/MAJ.0b013e3181b97635","article-title":"Efficacy of short-course, low-dose corticosteroid therapy for acute pulmonary sarcoidosis exacerbations","volume":"339","author":"McKinzie","year":"2010","journal-title":"Am J Med Sci"},{"key":"10.1016\/j.coi.2025.102637_bib66","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1136\/ard.2008.092163","article-title":"Dose-related patterns of glucocorticoid-induced side effects","volume":"68","author":"Huscher","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.coi.2025.102637_bib67","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1003432","article-title":"Dose-dependent oral glucocorticoid cardiovascular risks in people with immune-mediated inflammatory diseases: a population-based cohort study","volume":"17","author":"Pujades-Rodriguez","year":"2020","journal-title":"PLoS Med"},{"key":"10.1016\/j.coi.2025.102637_bib68","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1183\/09031936.00138913","article-title":"Relapses of sarcoidosis: what are they and can we predict who will get them?","volume":"43","author":"Baughman","year":"2014","journal-title":"Eur Respir J"},{"key":"10.1016\/j.coi.2025.102637_bib69","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s12016-015-8492-9","article-title":"Treatment of sarcoidosis","volume":"49","author":"Baughman","year":"2015","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.coi.2025.102637_bib70","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1378\/chest.127.3.1064","article-title":"Treatment of sarcoidosis with infliximab","volume":"127","author":"Doty","year":"2005","journal-title":"Chest"},{"key":"10.1016\/j.coi.2025.102637_bib71","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1016\/j.rmed.2006.02.017","article-title":"Effectiveness of infliximab in treating selected patients with sarcoidosis","volume":"100","author":"Saleh","year":"2006","journal-title":"Respir Med"},{"key":"10.1016\/j.coi.2025.102637_bib72","article-title":"Durable medication-free remission of sarcoidosis following discontinuation of anti-tumor necrosis factor-\u03b1 therapy","volume":"206","author":"Yee","year":"2022","journal-title":"Respir Med"},{"key":"10.1016\/j.coi.2025.102637_bib73","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.molimm.2017.08.010","article-title":"Role of neuropilin-2 in the immune system","volume":"90","author":"Schellenburg","year":"2017","journal-title":"Mol Immunol"},{"key":"10.1016\/j.coi.2025.102637_bib74","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/j.chest.2022.10.037","article-title":"Efzofitimod for the treatment of pulmonary sarcoidosis","volume":"163","author":"Culver","year":"2023","journal-title":"Chest"},{"key":"10.1016\/j.coi.2025.102637_bib75","doi-asserted-by":"crossref","DOI":"10.1097\/MCP.0000000000001196","article-title":"New therapeutic options in sarcoidosis","author":"Nunes","year":"2025","journal-title":"Curr Opin Pulm Med"}],"container-title":["Current Opinion in Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S095279152500113X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S095279152500113X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T13:23:59Z","timestamp":1757337839000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S095279152500113X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":75,"alternative-id":["S095279152500113X"],"URL":"https:\/\/doi.org\/10.1016\/j.coi.2025.102637","relation":{},"ISSN":["0952-7915"],"issn-type":[{"value":"0952-7915","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Can sarcoidosis be cured?","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.coi.2025.102637","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102637"}}